Differences

This shows you the differences between two versions of the page.

--- pgxp [2024/11/04 11:06] – trynke
+++ pgxp [2025/08/12 14:40] (current) – petra_vinke
@@ Line 14: / Line 14: @@
   - **uptake** in terms of (a) installing the application, (b) giving consent to receiving the PGx passport, (c) reading the information provided, and (d) sharing the information provided with their own healthcare professionals (when appropriate)?
-Potential determinants are sociodemographic characteristics, health status and use of medication, health literacy, perceived barriers, facilitators, and benefits of sharing the PGx passport.
+Sociodemographic characteristics, health status and use of medication, health literacy, perceived barriers, facilitators, and benefits of sharing the PGx passport were taken into account as potential determinants.
 ===== Protocol =====
 The pGxP study ran between April and July 2024.\\
-First, n=~4300 selected participants received an invitation to fill in a baseline PGxP questionnaire abou their health, medication use, digital skills, attitude toward DNA research and PGx passports. Participants were informed that if they filled in the questionnaire, they would be offered access to their personal PGxP via a smartphone app (if they were interested).\\
+  * First, n=~4300 selected participants received an invitation to fill in a baseline PGxP questionnaire abou their health, medication use, digital skills, attitude toward DNA research and PGx passports. Participants were informed that if they filled in the questionnaire, they would be offered access to their personal PGxP via a smartphone app (if they were interested).\\
-Of the n=~1150 respondents to the baseline PGxP questionnaire, n=~1000 participants also gave permission to upload their personal pharmacogenetic characteristics into the 'Gen en Geneesmiddel' app that they could then install and access on their smartohone.\\
+  * Of the n=~1150 respondents to the baseline PGxP questionnaire, n=~1000 participants also gave permission to upload their personal pharmacogenetic characteristics into the 'Gen en Geneesmiddel' app that they could then install and access on their smartohone.\\
-A total of n=~620 participants completed all the steps and received their personal information in the app.\\
+  * A total of n=~620 participants completed all the steps and received their personal information in the app.\\
-As a final step, all ~1150 respondents to the baseline PGxP questionnaire received a follow-up questionnaire containing questions on their decision-making process, opinion on the shared information and on the app, and the actual use of the PGxP (if applicable).
+  * As a final step, all ~1150 respondents to the baseline PGxP questionnaire received a follow-up questionnaire containing questions on their decision-making process, opinion on the shared information and on the app, and the actual use of the PGxP (if applicable).
+===== Publications =====
+The following publication was based on the PGXP Assessment:
+  * Lanting et al. (2025) [[https://www.cell.com/ajhg/abstract/S0002-9297(25)00102-8|Low-cost generation of clinical-grade, layperson-friendly pharmacogenetic passports using oligonucleotide arrays]]. AJHG 112(5): P1015-1028